China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for GQ1011 (AMB302). This FGFR3-targeted ADC was co-developed with South Korea-based biotech Aimed Bio under an agreement established in 2022 and is now set to be studied in solid tumors.
GQ1011 (AMB302): A Novel FGFR3-Targeting ADC
GQ1011 (AMB302) is a groundbreaking ADC that targets FGFR3, conjugated with an innovative topoisomerase I inhibitor (TopoIx). The drug utilizes GeneQuantum’s proprietary Ligase-Dependent Conjugation (iLDC) technology, which ensures high homogeneity, excellent druggability, and superior linker stability. These characteristics are crucial for the efficacy and safety of ADCs, making GQ1011 (AMB302) a promising candidate for the treatment of solid tumors.
Advancing ADC Technology with iLDC
The use of iLDC technology in the development of GQ1011 (AMB302) highlights GeneQuantum’s commitment to advancing ADC technology. This technology allows for the precise attachment of payloads to antibodies, enhancing the drug’s ability to target and destroy cancer cells while minimizing damage to healthy tissue.-Fineline Info & Tech
